GCTK (GlucoTrack) EBIT: $-16.80 Mil (TTM As of Mar. 2026)


GCTK GlucoTrack Inc GCTK
19 GF Score
Price $0.34
! 2 Warning Signs
View Full Analysis

What is GlucoTrack EBIT?

GlucoTrack GCTK -2.80% 19 EBIT is $-16.80 Mil as of Mar. 2026. GuruFocus rates GCTK with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

GlucoTrack's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-4.20 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-16.80 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. GlucoTrack's annualized ROC % for the quarter that ended in Mar. 2026 was -451.63%. GlucoTrack's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -10,742.49%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. GlucoTrack's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -939.32%.

GlucoTrack  (NAS:GCTK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

GlucoTrack's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-16.812 * ( 1 - 0% )/( (3.627 + 3.818)/ 2 )
=-16.812/3.7225
=-451.63 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7.838 - 1.317 - ( 7.383 - max(0, 4.773 - 7.667+7.383))
=3.627

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.356 - 1.299 - ( 3.929 - max(0, 4.975 - 4.214+3.929))
=3.818

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

GlucoTrack's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-16.812/( ( (0.171 + max(-1.279, 0)) + (0.142 + max(-1.334, 0)) )/ 2 )
=-16.812/( ( 0.171 + 0.142 )/ 2 )
=-16.812/0.1565
=-10,742.49 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.284) - (1.317 + 0 + 0.246)
=-1.279

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.285) - (1.299 + 0 + 0.32)
=-1.334

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

GlucoTrack's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-16.795/1.788
=-939.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlucoTrack EBIT Related Terms

GlucoTrack EBIT Historical Data

* Premium members only.

The historical data trend for GlucoTrack's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlucoTrack EBIT Chart

GlucoTrack Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.98 -4.43 -7.10 -14.55 -16.09

GlucoTrack Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.50 -4.80 -4.31 -3.49 -4.20

GCTK vs RSCF, CBSC, NXGL: EBIT Comparison

For the Medical Instruments & Supplies subindustry, GlucoTrack's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlucoTrack EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GlucoTrack's EV-to-EBIT falls into.


GCTK
19GF Score
GlucoTrack Inc GCTK
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlucoTrack EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-16.80 Mil mean?
GlucoTrack (GCTK) has a EBIT of $-16.80 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on GlucoTrack.
Is GlucoTrack's EBIT too high?
GlucoTrack's current EBIT is $-16.80 Mil. Overall, GlucoTrack has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GlucoTrack's EBIT compare to RSCF and CBSC?
GlucoTrack's EBIT of $-16.80 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on GlucoTrack. GlucoTrack's current EBIT is $-16.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlucoTrack stock overvalued right now?
GlucoTrack (GCTK) has a current EBIT of $-16.80 Mil. The current EBIT is $-16.80 Mil. GlucoTrack's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For GlucoTrack (GCTK), the current EBIT is $-16.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlucoTrack Business Description

Address 301 Route 17 North, Suite 800, Rutherford, NJ, USA, 07070
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
19GF Score

Get the complete analysis for GCTK

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price